SSO would like to thank the following companies for their support. Please select a name to learn more.
The Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation is a volunteer-led national 501(c)3 nonprofit organization whose core mission is to: 1. Fund and support research to discover new treatments for appendix cancer with the hope of one day finding a cure for all. 2. Fund and support educational programs for health care professionals and patients/caregivers & families to keep current with the evolving science and to increase awareness about this rare cancer.
Delcath Systems, Inc. is a commercial-stage interventional oncology company aiming to be the leader in targeted, safe and effective minimally-invasive treatments for patients with cancers in the liver.
Intera Oncology® Inc. is a Boston-based medical device company founded in 2019 by two doctors with a singular vision for improving the survival of colorectal cancer and cholangiocarcinoma patients by ensuring access to Hepatic Artery Infusion (HAI) therapy. Dedicated to helping patients live longer and better lives, Intera Oncology manufactures the only FDA-approved pump for HAI therapy – the Intera 3000 Hepatic Artery Infusion Pump.
PMP Pals is the world’s oldest, global, volunteer-run, peer-to-peer support community for patients and caregivers living with Appendix Cancer, Pseudomyxoma Peritonei (also known as PMP) and related peritoneal surface malignancies. We build emotional resilience by sharing our hope, experience, resources, and information with each other through programs and services that meet the challenges of this rare disease.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
ThermaSolutions is the global leader in Hyperthermic Medical Technology. We have established and will continue our leadership through extensive research, development and product innovation. ThermaSolutions manufactures and distributes the ThermoChem HT family of systems and customized procedure kits and disposables to assist in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedures. The HT-2000 device is utilized in more than 300 Oncology Centers throughout the United States, Europe, Latin America, Australia/New Zealand, Middle East, Africa, and Asia. ThermaSolutions is also proud to be one of the pioneers in aerosolization liquids during minimally invasive procedures. Our HurriChem device is the first to achieve both CE (for PIPAC) and FDA approval.